Key Players and Their Investments
The Mexican government, along with representatives from the domestic pharmaceutical industry, announced an investment of 10,480 million pesos to expand infrastructure, production capacity, and biotechnological development in the health sector.
- Kener: 5,180 million pesos for plant expansion in Toluca Industrial Park 2000.
- Genbio: 4,000 million pesos for plasma fractionation plant and additional capacity.
- BioGenTec: 800 million pesos for biofarmaceutical production, vacines, and biotechnological drug development.
- Neolsym: 500 million pesos for expanding national production of active pharmaceutical ingredients (API).
Government Officials Highlight Importance of the Investment
Marcelo Ebrard, Secretary of Economy, and David Kershenobich, Secretary of Health, emphasized the goal of achieving self-sufficiency in healthcare and technology to reduce dependence on foreign suppliers for medications and medical supplies.
“Do you remember the Covid-19 experience? We had to import vaccines and medications. Today, we are taking a firm step towards real pharmaceutical sovereignty,” Ebrard Casaubón stated.
Growth Opportunities and Technological Advancements
Ebrard highlighted that the pharmaceutical sector is one of Mexico’s fastest-growing fields, with a well-diagnosed platform to multiply its productive capacity. Kershenobich celebrated the incorporation of original innovation and cutting-edge technology in most projects, including Mexico’s first plasma fractionation plant, unique in Latin America.
Specific Project Announcements
- Kener: Expansion of its Toluca plant with a 5,180 million pesos investment, including a third-generation CAR-T cell production facility (unique in Latin America) and new lines for hospital injectables, oncology, and integrated anesthesia services.
- Genbio: Already invested 2,400 million pesos in a plasma fractionation plant and will add 1,600 million pesos to increase production of plasma-derived medications like albumin and coagulation factors, making Mexico a regional leader in this area.
- BioGenTec: Announced investments in eight projects, with two in advanced stages. These plans involve biofarmaceutical production, vaccine development, and biotechnological drug creation in collaboration with various Mexican universities.
- NeolSyM: 500 million pesos investment to expand national production of active pharmaceutical ingredients (API) with plants in Ecatepec, State of Mexico, and Jiutepec, Morelos, aiming to reduce the current 90% dependence on imported raw materials.
Key Questions and Answers
- Who are the key players involved in this investment? The main participants are Kener, Genbio, BioGenTec, and Neolsym, all Mexican pharmaceutical companies.
- What is the total investment amount? The total investment is 10,480 million pesos.
- What are the primary goals of this investment? The main objectives are to expand infrastructure, production capacity, and biotechnological development in the health sector, aiming for self-sufficiency in healthcare and technology.
- What specific projects have been announced? Projects include CAR-T cell production, plasma fractionation, biofarmaceutical development, vaccine creation, and expanded API production.
